Lumos Secures Fifth US Medicare Reimbursement for FebriDx®
19 May 2025
Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another Medicare Administrative Contractors (MACs), WPS Health Solutions (WPS), retroactive from 1 May 2025.
Lumos now has Medicare reimbursement from five of the seven MACs, representing over 70% of the total US Medicare payment coverage. Negotiations are ongoing with the remaining two MACs.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“Securing additional Medicare coverage from WPS for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.
Lumos remains committed to securing adoption from the remaining two MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Click to read the ASX release.
Lumos now has Medicare reimbursement from five of the seven MACs, representing over 70% of the total US Medicare payment coverage. Negotiations are ongoing with the remaining two MACs.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“Securing additional Medicare coverage from WPS for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.
Lumos remains committed to securing adoption from the remaining two MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Click to read the ASX release.
